>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

3.20 0.02 (0.63%) 10/02/2026
Evaxion Biotech A/S (EVAX)
Performance
Historical returns
1D
0.63%
1W
-1.23%
1M
4.23%
3M
-6.16%
6M
-15.34%
1Y
-32.49%
5Y
-99.26%
Snapshot
Key statistics
Close
3.20
Change
0.02
Change %
0.63%
Open
3.23
Day Range
3.16 – 3.28
Volume
33,888
Avg Vol (20d)
42,655
Rel Vol
0.79x
52W Range
2.77 - 12.15
vs 52W High
-73.66%
vs 52W Low
15.52%
Gap
0.00
Market Cap
USD 20.21M
Beta
0.29
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Create a free account
Bull vs Bear
2 bullish · 6 bearish points
Bullish view
  • Consensus looks for 104.7% revenue growth in 2028 to $15.41M.
  • Consensus has EPS compounding 41.4% a year to $0.06 by 2030, which grows the multiple down to 53.3×.
Bearish view
  • Revenue fell 100.0% year on year in the Jun 2026 quarter.
  • FY2025 earnings fell 26.8% to -$7.73M.
  • Trades at 107× the 2028 consensus EPS of $0.03, a multiple that leaves little room for disappointment.
  • Trades 13.4% below its 200-day average, a downtrend still intact.
  • Still 70.9% below its 52-week high of $11.01.
  • Missed consensus EPS in 4 of the last 7 quarters.
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Oct 2
2026
$3.20 0.63%Latest
Evaxion Biotech A/S rose 0.63% to $3.20. Shares opened with a 1.57% gap up and reclaimed their 20-day moving average. The move left the stock 70.9% below its 52-week high.
Oct 1
2026
$3.18 3.05%
Evaxion Biotech A/S fell 3.05% to $3.18, its biggest one-day drop in 3 weeks. Roughly 1.7 points were stock-specific — the S&P 500 gained 0.18% while Healthcare peers (XLV) fell 1.32% alongside it. Shares opened with a 2.13% gap down and lost their 20-day moving average.
Sep 28
2026
$3.24 2.99%
Evaxion Biotech A/S fell 2.99% to $3.24, its biggest one-day drop in 2 weeks. This was largely stock-specific: the S&P 500 fell 0.74% while Healthcare peers (XLV) rose 0.33% that session, leaving about 2.8 points of the move unexplained by the market after adjusting for a 0.29 beta. Shares opened with a 0.90% gap down.
Sep 17
2026
$3.22 6.27%
Evaxion Biotech A/S rose 6.27% to $3.22, its biggest one-day gain in 3 months and a 2.2σ move against its 60-day volatility, though on light volume (0.1× the 20-day average). This was largely stock-specific: the S&P 500 gained 1.39% while Healthcare peers (XLV) rose 0.62% that session, leaving about 5.7 points of the move unexplained by its sector. Shares opened with a 2.97% gap up, closed near the session high (88% of the day's range) and reclaimed their 20- and 50-day moving averages. Historically, after 2.2σ-or-larger up days, Evaxion Biotech A/S returned -5.73% on average over the following 5 sessions (41% positive, n=22).
Sep 10
2026
$3.10 5.78%
Evaxion Biotech A/S fell 5.78% to $3.10, its biggest one-day drop in 3 weeks and a 1.7σ move against its 60-day volatility, though on light volume (0.2× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.60% while Healthcare peers (XLV) fell 0.55% that session, leaving about 5.2 points of the move unexplained by its sector. Shares opened with a 0.76% gap down, closed near the session low (0% of the day's range) and lost their 20-day moving average.
Sep 9
2026
$3.29 3.79%
Evaxion Biotech A/S rose 3.79% to $3.29, its biggest one-day gain in 3 weeks, though on light volume (0.1× the 20-day average). This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.33% that session, leaving about 3.9 points of the move unexplained by the market after adjusting for a 0.29 beta. Shares opened with a 2.21% gap up, closed near the session high (89% of the day's range) and marked a 5th consecutive advance.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month2.99 +7.02%
on 09/02/26
Open 3.07
3.35 -4.48%
on 09/23/26
+0.13 (+4.23%)
since 09/02/26
3-Month2.77 +15.52%
on 08/03/26
Open 3.38
3.64 -12.01%
on 08/20/26
-0.18 (-5.33%)
since 07/06/26
6-Month2.77 +15.52%
on 08/03/26
Open 3.78
4.75 -32.63%
on 05/04/26
-0.58 (-15.34%)
since 04/02/26
YTD2.77 +15.52%
on 08/03/26
Open 4.71
5.48 -41.61%
on 01/07/26
-1.51 (-32.06%)
since 01/02/26
52-Week2.77 +15.52%
on 08/03/26
Open 4.44
12.15 -73.66%
on 10/15/25
-1.24 (-27.93%)
since 10/01/25
5-Year1.20 +166.67%
on 04/10/25
Open 477.50
500.00 -99.36%
on 09/27/21
-474.30 (-99.33%)
since 09/24/21
New Highs
Historical highs
5-Day
2×
-2.44% from peak
1-Month
4×
-4.19% from peak
3-Month
2×
-5.88% from peak
6-Month
8×
-29.98% from peak
YTD
3×
-40.63% from peak
52-Week
4×
-70.94% from peak
2-Year
0×
-79.42% from peak
3-Year
7×
-94.53% from peak
5-Year
0×
-99.34% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
USD 7.53M
+125.1% YoY
Net Income
-USD 7.73M
-26.8% YoY
EPS
-1.21
-87.7% YoY
Gross Margin
100.0%
Operating Margin
-122.7%
Net Margin
-102.7%
EBITDA
-USD 7.12M
Free Cash Flow
-USD 6.66M
-88.4% margin
ROE
-45.4%
ROA
-27.2%
Debt / Equity
0.44x
net debt -USD 15.73M
Cash & Equiv.
USD 23.23M
News
All news
10/02 09:00 ET · globenewswire.com
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for...
09/17 03:32 ET · defenseworld.net
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional...
09/14 08:00 ET · globenewswire.com
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher...
08/20 12:31 ET · seekingalpha.com
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
08/20 07:30 ET · globenewswire.com
Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.
08/17 08:00 ET · globenewswire.com
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma.
08/14 08:00 ET · globenewswire.com
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20,...
07/17 07:15 ET · globenewswire.com
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate...

Market News ×
Loading news…